Your shopping cart is currently empty

NSC348884 is a nucleophosmin inhibitor disrupts oligomer formation and induces apoptosis, inhibits cell proliferation at an IC50 of 1.7-4.0 μM in distinct cancer cell lines.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 2 mg | $35 | In Stock | In Stock | |
| 5 mg | $56 | In Stock | In Stock | |
| 10 mg | $97 | In Stock | In Stock | |
| 25 mg | $190 | In Stock | In Stock | |
| 50 mg | $312 | In Stock | In Stock | |
| 100 mg | $450 | In Stock | In Stock | |
| 500 mg | $987 | - | In Stock | |
| 1 mL x 10 mM (in DMSO) | $77 | In Stock | In Stock |
| Description | NSC348884 is a nucleophosmin inhibitor disrupts oligomer formation and induces apoptosis, inhibits cell proliferation at an IC50 of 1.7-4.0 μM in distinct cancer cell lines. |
| Targets&IC50 | Nucleophosmin:1.7-4.0 μM |
| In vitro | NSC348884 disrupts a defined hydrophobic pocket required for oligomerization. NSC348884 disrupts nucleophosmin oligomer formation by native polyacrylamide gel electrophoresis assay. NSC348884 upregulates p53. NSC348884 induces apoptosis. |
| In vivo | In vivo invasion and intravasation (that is, the number of CTCs) are significantly inhibited after injection of NSC348884(as an inhibitor of NPM1 oligomerization) into the tumor-bearing mice. No significant difference in overall cell death is observed by histology in the treated tumors with the 4-hour brief treatments, suggesting that the inhibition seen is specific to migration.[2]. |
| Molecular Weight | 636.79 |
| Formula | C38H40N10 |
| Cas No. | 81624-55-7 |
| Smiles | Cc1ccc2nc(CN(CCN(Cc3nc4ccc(C)cc4[nH]3)Cc3nc4ccc(C)cc4[nH]3)Cc3nc4ccc(C)cc4[nH]3)[nH]c2c1 |
| Relative Density. | 1.347g/cm3 |
| Storage | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 255 mg/mL (400.45 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+90% Corn Oil: 2.5 mg/mL (3.93 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.